Biovica is a bio-diagnostic company founded in 2009 and based on research from Uppsala University.

Biovica’s innovative technology, the DiviTum™ assay, measures the rate of cell proliferation to determine tumor aggressiveness and growth rate. Biovicas’s initial focus is breast cancer. The company works with leading cancer institutes, collaborative groups, and pharmaceutical companies on product development, with the aim of improving outcomes and lowering costs.